Cargando…

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer()

INTRODUCTION: The presence of KRAS mutations in patients with metastatic colorectal cancer (mCRC) predicts poor response to agents targeting the EGFR. Even in patients with RAS wild type (WT) tumors, resistance eventually develops due to multiple mechanisms, including the expansion of previously und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matikas, Alexios, Voutsina, Alexandra, Lagoudaki, Eleni, Hatzidaki, Dora, Trypaki, Maria, Stoupis, Giannis, Tzardi, Maria, Mavroudis, Dimitrios, Georgoulias, Vasilios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503828/ https://www.ncbi.nlm.nih.gov/pubmed/28692881 http://dx.doi.org/10.1016/j.tranon.2017.06.005

Ejemplares similares

Role of circulating free DNA in colorectal cancer
por: Matikas, Alexios, et al.
Publicado: (2016)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
por: Koulouridi, Asimina, et al.
Publicado: (2022)

Expression of insulin‐like growth factor‐1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes
por: Spiliotaki, Maria, et al.
Publicado: (2017)

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2019)

KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer
por: Kalikaki, Aristea, et al.
Publicado: (2014)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2(nd) Line Cetuximab-Based Therapy of Colorectal Cancer Patients
por: Saridaki, Zacharenia, et al.
Publicado: (2011)

Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide
por: Karachaliou, Niki, et al.
Publicado: (2013)

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
por: Saridaki, Z, et al.
Publicado: (2012)

Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study
por: Papadaki, Chara, et al.
Publicado: (2020)

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2022)

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
por: Vamvakas, Lambros, et al.
Publicado: (2014)

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer
por: Polioudaki, Hara, et al.
Publicado: (2015)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients’ Outcome
por: Saridaki, Zacharenia, et al.
Publicado: (2013)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
por: Nikolaou, Christos, et al.
Publicado: (2015)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
por: Matikas, Alexios, et al.
Publicado: (2015)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2020)

Clinical value and feasibility of ISET in detecting circulating tumor cells in early breast cancer
por: Zeng, Hanling, et al.
Publicado: (2020)

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group
por: Mavroudis, Dimitrios, et al.
Publicado: (2017)

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy
por: Kotsakis, A, et al.
Publicado: (2016)

Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies
por: Koulouris, Andreas, et al.
Publicado: (2021)

Brain and bone marrow metastases from rectal cancer
por: Thomopoulou, Konstantina, et al.
Publicado: (2020)

Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application
por: Chen, Fangfang, et al.
Publicado: (2016)

Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer
por: Papadaki, Chara, et al.
Publicado: (2019)

Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer
por: Messaritakis, Ippokratis, et al.
Publicado: (2018)

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
por: Farace, F, et al.
Publicado: (2011)

Complete Genome Sequence of a Virulent Strain, Streptococcus iniae ISET0901, Isolated from Diseased Tilapia
por: Pridgeon, Julia W., et al.
Publicado: (2014)

Predictive Value of Circulating Tumor Cells Detected by ISET(®) in Patients with Non-Metastatic Prostate Cancer Undergoing Radical Prostatectomy
por: Garrido Castillo, Laura Nalleli, et al.
Publicado: (2022)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

Evaluation of Microsatellite Instability Molecular Analysis versus Immuno-Histochemical Interpretation in Malignant Neoplasms with Different Localizations
por: Sfakianaki, Maria, et al.
Publicado: (2023)

Prognostic Value of KRAS Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients
por: Guo, Tianan, et al.
Publicado: (2021)

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer
por: Daskalaki, A, et al.
Publicado: (2009)

SensiScreen(®) KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations
por: Riva, Alice, et al.
Publicado: (2017)

Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch(®) and ISET
por: Tamminga, Menno, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ctrr02kc9i57g4f8cm1t2ggpri